Although there is great concern over emerging viruses and viruses on the NIAID category A-C priority pathogen lists, there are relatively few prophylactics or therapeutics for these viruses, and most which do exist are highly pathogen-specific or have undesirable side effects or other disadvantages. We have developed a radically new and very broad-spectrum antiviral therapeutic/prophylactic that has the potential to revolutionize the treatment of viral infections, including those due to emerging, category A-C, and common clinical pathogens. Our dsRNA (double-stranded RNA) activated caspase (DAC) approach selectively induces apoptosis in cells containing any viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have previously created a DAC and shown that it is nontoxic and effective against 10 different viruses in 10 mammalian cell types. We have also demonstrated that it is nontoxic in mice and rescues mice from a lethal H1N1 influenza challenge. A large number of viruses on the category A-C lists belong to the arenavirus, bunyavirus, and flavivirus families, virus families against which we have not previously tested DAC. Therefore, the experimental focus of this proposal is to test DAC against representative members of these virus families.
The specific aims are to: 1. Demonstrate efficacy in multiple mammalian cell types against representative members of the arenavirus, bunyavirus, and flavivirus families. 2. Perform DAC pharmacokinetic analyses and assess DAC immunogenicity in vivo. 3. Demonstrate antiviral efficacy in a lethal mouse model using the best challenge virus from the in vitro trials. Success in these aims should demonstrate the potential of DAC to treat arenaviruses, bunyaviruses, and flaviviruses and pave the way for further trials with additional viruses and animal models. This work should greatly advance DAC toward ultimate utility as a safe, broad-spectrum therapeutic/prophylactic for NIAID priority and emerging viral pathogens, filling a large gap in existing therapeutics and directly supporting NERCE's mission.

Public Health Relevance

Success in the proposed work should greatly advance DAC toward ultimate utility as a safe, broad-spectrum therapeutic/prophylactic for NIAID priority viral pathogens, filling a large gap in existing therapeutics and directly supporting NERCE's mission.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057159-10
Application #
8617037
Study Section
Special Emphasis Panel (ZAI1-DDS-M (J1))
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
10
Fiscal Year
2013
Total Cost
$172,903
Indirect Cost
$53,681
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Clark, Margaret J; Miduturu, Chandra; Schmidt, Aaron G et al. (2016) GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem Biol 23:443-52
Russo, Brian C; Stamm, Luisa M; Raaben, Matthijs et al. (2016) Intermediate filaments enable pathogen docking to trigger type 3 effector translocation. Nat Microbiol 1:16025
Kirienko, Daniel R; Revtovich, Alexey V; Kirienko, Natalia V (2016) A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa Virulence. mSphere 1:
Taylor, Travis J; Diaz, Fernando; Colgrove, Robert C et al. (2016) Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology 496:186-93
Chou, Yi-ying; Cuevas, Christian; Carocci, Margot et al. (2016) Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol 90:4494-510
Mellata, Melha; Mitchell, Natalie M; Schödel, Florian et al. (2016) Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis. Vaccine 34:656-62
Helenius, Iiro Taneli; Nair, Aisha; Bittar, Humberto E Trejo et al. (2016) Focused Screening Identifies Evoxine as a Small Molecule That Counteracts CO2-Induced Immune Suppression. J Biomol Screen 21:363-71
Stone, Laura K; Baym, Michael; Lieberman, Tami D et al. (2016) Compounds that select against the tetracycline-resistance efflux pump. Nat Chem Biol 12:902-904
Balasubramanian, Anuradha; Manzano, Mark; Teramoto, Tadahisa et al. (2016) High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antiviral Res 134:6-16
Vrentas, Catherine E; Moayeri, Mahtab; Keefer, Andrea B et al. (2016) A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. J Biol Chem 291:21596-21606

Showing the most recent 10 out of 401 publications